Allergan, Inc. (NYSE:AGN) announced the United States Food and Drug Administration (FDA) has approved LUMIGAN® (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGAN® 0.01% is an optimized reformulation of LUMIGAN® (bimatoprost ophthalmic solution) 0.03 ...

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Allergan Inc. Posted on:01 Sep 10 Allergan, Inc. (NYSE:AGN) today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN® (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IRVINE, Calif.----Allergan, Inc. today announced the United States Food and Drug Administration has approved LUMIGAN® 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

The US Food and Drug Administration (FDA) approved Tekamlo® (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren) with the widely used calcium channel blocker, amlodipine1. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood ...